NCT04084197

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.

An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

An open-label, randomized, single-dose crossover study to evaluate the pharmacokinetics, safety and tolerability of HIP1801 in healthy male subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	HIP1402	Tamsulosin (HanmiTams Capsule) 0.4mg
DRUG	HIP1801	Tamsulosin 0.4mg

Timeline

• Start date: 2018-12-19
• Primary completion: 2018-12-31
• Completion: 2019-01-04
• First posted: 2019-09-10
• Last updated: 2019-09-10

Locations

1 site across 1 country: South Korea